Prevail Therapeutics Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2020. For the quarter, Total operating loss was $18,624,000 against $21,288,000 reported a year ago. Net loss was $18,587,000 against $20,299,000 reported a year ago. Net loss per share, basic and diluted was $0.55 against $0.62 reported a year ago. For the nine months, Total operating loss was $60,054,000 against $47,252,000 reported a year ago. Net loss was $59,262,000 against $45,347,000 reported a year ago. Net loss per share, basic and diluted was $1.77 against $1.68 reported a year ago.